Every week my Google Scholar alerts — tuned to capitation, DRGs, strategic purchasing and UHC — sweep what the world’s health systems are publishing about the experiments South Africa is still designing. This is the first of a weekly read of that haul. This week alone: England published the mechanics of the world’s most scrutinised capitation formula, the World Bank recommended Malaysia move toward DRGs, and Nigerian and Philippine researchers asked whether their insurance schemes’ machinery actually works — landing alongside recent results from China and Central Asia on what DRGs do in practice. South Africa is designing NHI in the middle of the richest comparator evidence base any UHC reform has ever had. The debate here rarely touches it.

Start with capitation, since it is the payment mechanism NHI proposes for primary care. This week the Health Foundation published a technical account of how English general practice is funded — centred on the Carr-Hill formula, the risk-adjustment methodology that weights each practice’s patient list to determine its core payment. What should strike a South African reader is not the formula’s sophistication but its age and its scars: this is a capitation system refined over decades, in a data-rich, single-payer system — and it remains contested, with live disputes about whether the weighting tracks need and workload. The lesson is not “copy Carr-Hill.” It is that no country has ever written a correct capitation formula on the first attempt. What the mature systems built was not a perfect formula but the machinery for revising one — data flows, review cycles, a legitimate process for losers to appeal. An NHI capitation design without that machinery is not a simpler version of England’s; it is a formula with no way to learn.

Next, hospital payment, where the comparator evidence is genuinely double-edged. This week’s clearest signal is from Malaysia, where a World Bank analysis of the country’s first centralised private-insurance claims database recommends provider payment reform away from itemised fee-for-service and a phased move toward DRG-based case payment — there, DRGs are the medicine, prescribed against the cost inflation that fee-for-service breeds. But the systems that took the medicine earlier are reporting side effects. A new Chinese study this week shows how catheter-related infections scatter costs across 26 DRG categories, leaving hospitals financially exposed for complications the tariff never priced. It lands on top of two results from recent weeks’ alerts: a Chinese evaluation of the 2020 DRG reform in Zhejiang that found efficiency gains alongside a rising complication trend in paediatric care — the signature of providers adapting to fixed case rates — and Central Asian researchers documenting a system that moved rural hospitals from DRGs back to global budgets, a deliberate reversal, because activity-based payment was punishing exactly the low-volume rural providers a public system most needs to keep alive. Read together, these are not arguments for or against DRGs. They are evidence that the same instrument is a cure in one context and an injury in another — and that rural carve-outs, complication risk-adjustment and outlier payments are not refinements to add later but load-bearing parts of the initial design. South Africa’s rural-urban provider landscape looks far more like Kazakhstan’s than like Kuala Lumpur’s.

Third — and least discussed in our debate — the machinery of purchasing itself. A Mongolian health-economics team’s comparative review of cost containment across the US, Germany, Japan, South Korea and Mongolia, from an earlier week’s alerts, reaches a finding that should interest both NHI’s architects and its critics: systems combining universal coverage with centralised price regulation give the purchaser real leverage over spending growth, and stronger purchasing arrangements contain costs better. That is, on its face, evidence for the single-purchaser logic. But two papers from this week supply the caveat that keeps the finding honest. Nigerian researchers evaluating the Edo State Health Insurance Scheme assess it through a state-capacity lens — asking not whether the benefit design is sound on paper, but whether the administrative machinery of the state can actually run it fairly. And a Philippine team has proposed something quietly brilliant: the “PhilHealth share ratio” — tracking what proportion of public facilities’ revenue actually flows through the national purchaser, as a hard empirical test of whether strategic purchasing is displacing the old money flows or merely coexisting with them. A purchaser’s power to contain costs, in other words, is only as real as the state’s capacity to operate it — and both are measurable. An NHI Fund monitoring framework could adopt the share-ratio metric almost unchanged.

None of this settles South Africa’s political argument, and it shouldn’t. What the comparator literature does is convert slogans into design questions with evidence attached: not “capitation yes or no” but “what revision machinery does the formula need”; not “DRGs yes or no” but “which providers need carve-outs from day one”; not “can the state run a purchaser” as rhetoric but as a measurable ratio. This is the cheapest technical assistance NHI will ever receive — peer-reviewed, free, and arriving weekly. I’ll be reading it here every week. These open questions are also precisely what the SP4UHC research webinar series — Strategic Purchasing for UHC: The Open Questions — exists to argue about, monthly from 7 October 2026 at Wits Family Medicine. If this piece raised a question you want contested properly, register and bring it — registrants also receive this weekly read by email.

Also from this week’s scholar alerts: